0001193125-16-614056.txt : 20160606 0001193125-16-614056.hdr.sgml : 20160606 20160606164917 ACCESSION NUMBER: 0001193125-16-614056 CONFORMED SUBMISSION TYPE: S-3ASR PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20160606 DATE AS OF CHANGE: 20160606 EFFECTIVENESS DATE: 20160606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Catalent, Inc. CENTRAL INDEX KEY: 0001596783 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208737688 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: S-3ASR SEC ACT: 1933 Act SEC FILE NUMBER: 333-211872 FILM NUMBER: 161699020 BUSINESS ADDRESS: STREET 1: 14 SCHOOLHOUSE ROAD CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: (732) 537-6200 MAIL ADDRESS: STREET 1: 14 SCHOOLHOUSE ROAD CITY: SOMERSET STATE: NJ ZIP: 08873 FORMER COMPANY: FORMER CONFORMED NAME: PTS Holdings Corp. DATE OF NAME CHANGE: 20140113 S-3ASR 1 d192455ds3asr.htm S-3ASR S-3ASR
Table of Contents

As filed with the Securities and Exchange Commission on June 6, 2016.

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Catalent, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   2834   20-8737688

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification No.)

14 Schoolhouse Road

Somerset, New Jersey 08873

(732) 537-6200

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

Steven Fasman, Esq.

Senior Vice President, General Counsel and Secretary

Catalent, Inc.

14 Schoolhouse Road

Somerset, New Jersey 08873

(732) 537-6200

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copy to:

Edward P. Tolley III, Esq.

Simpson Thacher & Bartlett LLP

425 Lexington Avenue

New York, NY 10017

Telephone: (212) 455-2000

Facsimile: (212) 455-2502

 

 

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ¨

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”) other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  x

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  x

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title Of Each Class Of
Securities To Be Registered
  Amount
to be
Registered(1)
  Proposed
Maximum
Offering Price
Per Share(1)
  Proposed
Maximum
Aggregate
Offering Price(1)
  Amount of
Registration Fee(2)

Common Stock, par value $0.01 per share

               

 

 

(1) Omitted pursuant to General Instructions II.E of Form S-3. An indeterminate amount of shares of common stock are being registered as may from time to time be issued at indeterminate prices.
(2) In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of the registration fee. Registration fees will be paid subsequently on a “pay as you go” basis.

 

 

 


Table of Contents

Prospectus

 

LOGO

Catalent, Inc.

Common Stock

 

 

We and any selling stockholder may offer and sell from time to time shares of our common stock.

We will determine when we sell shares of our common stock, which may be sold on a continuous or delayed basis directly, to or through agents, dealers or underwriters as designated from time to time, or through a combination of these methods. We reserve the sole right to accept, and we and any agents, dealers and underwriters reserve the right to reject, in whole or in part, any proposed purchase of shares of our common stock. If any agents, dealers or underwriters are involved in the sale of any shares of our common stock, the applicable prospectus supplement will set forth any applicable commissions or discounts payable to them. Our net proceeds from the sale of the shares of our common stock will be set forth in the applicable prospectus supplement. We also may provide you with a free writing prospectus that includes this information. In addition, certain selling stockholders may offer and sell shares of our common stock from time to time, together or separately, in amounts, at prices and on terms that will be determined at the time of any such offering.

Each time that we or any selling stockholders sell shares of our common stock using this prospectus, we or any selling stockholders will provide a prospectus supplement and attach it to this prospectus and may also provide you with a free writing prospectus. The prospectus supplement and any free writing prospectus will contain more specific information about the offering and the shares of our common stock being offered, including the names of any selling stockholders, if applicable, the prices and our net proceeds from the sales of those shares of our common stock. The prospectus supplement or free writing prospectus may also add, update, change or clarify information contained in or incorporated by reference into this prospectus. This prospectus may not be used to sell shares of our common stock unless accompanied by a prospectus supplement describing the method and terms of the offering.

You should carefully read this prospectus and any applicable prospectus supplement and free writing prospectus, together with any documents we incorporate by reference, before you invest in our common stock.

Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “CTLT”.

Investing in our common stock involves risks. You should carefully consider the risk factors referred to on page 2 of this prospectus, in any applicable prospectus supplement and in the documents incorporated or deemed incorporated by reference in this prospectus before investing in our common stock.

 

 

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

 

 

Prospectus dated June 6, 2016.


Table of Contents

TABLE OF CONTENTS

 

     Page  

Summary

     1   

Risk Factors

     2   

Forward-Looking Statements

     3   

Trademarks and Service Marks

     3   

Use of Proceeds

     4   

Selling Stockholders

     5   
     Page  

Description of Capital Stock

     6   

Plan of Distribution

     14   

Legal Matters

     16   

Experts

     16   

Where You Can Find More Information

     16   

Information Incorporated by Reference

     16   
 

 

This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under this shelf registration process, we and/or certain selling stockholders, if applicable, may, from time to time, offer and/or sell shares of our common stock in one or more offerings or resales. This prospectus provides you with a general description of the shares of our common stock that we and/or certain selling stockholders may offer. Each time we sell shares of our common stock using this prospectus, we will provide a prospectus supplement and attach it to this prospectus and may also provide you with a free writing prospectus. The prospectus supplement and any free writing prospectus will contain more specific information about the offering and the shares of our common stock being offered, including the names of any selling stockholders, if applicable, the prices and our net proceeds (if any) from the sales of those shares of common stock. The prospectus supplement may also add, update, change or clarify information contained in or incorporated by reference into this prospectus. If there is any inconsistency between the information in this prospectus and the information in the prospectus supplement, you should rely on the information in the prospectus supplement.

The rules of the SEC allow us to incorporate by reference information into this prospectus. This means that important information is contained in other documents that are considered to be a part of this prospectus. Additionally, information that we file later with the SEC will automatically update and supersede this information. You should carefully read both this prospectus and the applicable prospectus supplement together with the additional information that is incorporated or deemed incorporated by reference in this prospectus. See “Information Incorporated by Reference” before making an investment in our common stock. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of the documents referred to herein have been filed or will be filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. The registration statement, including the exhibits and documents incorporated or deemed incorporated by reference in this prospectus, can be read on the SEC website or at the SEC offices mentioned under the heading “Where You Can Find More Information.”

THIS PROSPECTUS MAY NOT BE USED TO SELL ANY SHARES OF OUR COMMON STOCK UNLESS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.

Neither the delivery of this prospectus or any applicable prospectus supplement nor any sale made using this prospectus or any applicable prospectus supplement implies that there has been no change in our affairs or that the information in this prospectus or in any applicable prospectus supplement is correct as of any date after their respective dates. You should not assume that the information included in or incorporated by reference in this prospectus or any applicable prospectus supplement or any free writing prospectus prepared by us, is accurate as of any date other than the date(s) on the front covers of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates.

You should rely only on the information contained in or incorporated by reference in this prospectus or a prospectus supplement. We have not authorized anyone to give you different information, and if you are given any information that is not contained or incorporated by reference in this prospectus or a prospectus supplement,

 

i


Table of Contents

you must not rely on that information. We and any selling stockholders are not making an offer to sell securities in any jurisdiction where the offer or sale of such securities is not permitted.

 

 

Except where the context requires otherwise, references in this prospectus to “Catalent,” the “Company,” “we,” “us,” and “our” refer to Catalent, Inc., together with its consolidated subsidiaries. In this prospectus, when we refer to our fiscal years, we say “fiscal” and the year number, as in “fiscal 2015,” which refers to our fiscal year ended June 30, 2015.

We refer in this prospectus to (i) investment funds associated with or designated by The Blackstone Group L.P. as “Blackstone” or “Sponsor” and (ii) our Annual Report on Form 10-K for the fiscal year ended June 30, 2015 as amended by Amendment No. 1 to such Annual Report on Form 10-K/A as our “2015 Form 10-K.”

 

ii


Table of Contents

SUMMARY

This summary highlights information contained elsewhere or incorporated by reference in this prospectus or any prospectus supplement and does not contain all of the information you should consider before investing in shares of our common stock. You should read this entire prospectus, any prospectus supplement, the documents incorporated herein or therein and any free writing prospectus prepared by us or on our behalf carefully, including the section entitled “Risk Factors” and the financial statements and the related notes incorporated by reference in this prospectus, before you decide to invest in shares of our common stock.

Our Company

We are the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, we have proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. We employ approximately 8,900 people, including over 1,000 scientists and technicians, at 31 facilities across five continents and in fiscal 2015 generated more than $1.8 billion in annual revenue.

For a description of our business, financial condition, results of operations and other important information regarding us, we refer you to our filings with the SEC incorporated by reference in this prospectus. For instructions on how to find copies of these documents, see “Where You Can Find More Information.”

Catalent, Inc. is a Delaware corporation. Our principal executive offices are located at 14 Schoolhouse Road, Somerset, New Jersey 08873, and our telephone number is (732) 537-6200. We maintain a website at www.catalent.com. The information contained on or accessible through our website neither constitutes part of this prospectus nor is incorporated by reference in this prospectus.

 



 

1


Table of Contents

RISK FACTORS

Investing in our common stock involves risks. You should carefully consider the risks and uncertainties discussed in our 2015 Form 10-K, which is incorporated by reference in this prospectus, under the caption “Risk Factors,” as well as other risks and uncertainties discussed under this caption or any similar caption in the other documents and reports that we file with the SEC on or after the date of this prospectus that are incorporated or deemed to be incorporated by reference in this prospectus as well as other risks and uncertainties described in any applicable prospectus supplement or free writing prospectus that we provide you in connection with an offering of common stock pursuant to this prospectus. These risks and uncertainties could materially affect our business, results of operations or financial condition and cause the value of our common stock to decline. You could lose all or part of your investment.

 

2


Table of Contents

FORWARD-LOOKING STATEMENTS

This prospectus (including any prospectus supplement and the information incorporated or deemed to be incorporated by reference in this prospectus) and any free writing prospectus that we may provide to you in connection with an offering of our common stock described in this prospectus contain forward-looking statements that reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. We believe these factors include but are not limited to those described under “Risk Factors” in the 2015 Form 10-K. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included, incorporated by reference or deemed to be incorporated by reference in this prospectus. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

TRADEMARKS AND SERVICE MARKS

“ADVASEPT®,” “GPEx®,” “OptiForm®,” “Liqui-Gels®,” “VegiCaps®,” “Zydis®” and “Zydis®Nano” are our registered U.S. and/or foreign trademarks. This prospectus also includes trademarks and trade names owned by other parties, and these trademarks and trade names are the property of their respective owners. We use certain other trademarks and service marks, including Easyburst™, Galacorin™, OptiGel™, OptiGel Bio™, OptiMelt™, OptiPact™, OptiShell™, Savorgel™, SMARTag™, Softdrop™ and Zydis Bio™ on an unregistered basis in the United States.

Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the ® and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks, and trade names.

 

3


Table of Contents

USE OF PROCEEDS

In the case of a sale of shares of our common stock by us, the use of proceeds will be specified in the applicable prospectus supplement. In the case of a sale of shares of our common stock by any selling stockholders, we will not receive any of the proceeds from such sale.

 

4


Table of Contents

SELLING STOCKHOLDERS

Information about selling stockholders, where applicable, will be set forth in a prospectus supplement, in a post-effective amendment or in filings we will make with the SEC, which are incorporated into this prospectus by reference.

 

5


Table of Contents

DESCRIPTION OF CAPITAL STOCK

The following is a description of the material terms of, and is qualified in its entirety by, our amended and restated certificate of incorporation and amended and restated bylaws, each of which are filed as exhibits to the registration statement of which this prospectus is a part.

Our purpose is to engage in any lawful act or activity for which corporations may now or hereafter be organized under the General Corporation Law of the State of Delaware (the “DGCL”). Our authorized capital stock consists of 1,000,000,000 shares of common stock, par value $0.01 per share, and 100,000,000 shares of preferred stock, par value $0.01 per share. No shares of preferred stock are issued or outstanding as of the date of this prospectus. Unless our board of directors determines otherwise, we will issue all shares of our capital stock in uncertificated form.

Common Stock

Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders, including the election or removal of directors. The holders of our common stock do not have cumulative voting rights in the election of directors. Upon our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of our common stock will be entitled to receive pro rata our remaining assets available for distribution. Holders of our common stock do not have preemptive, subscription, redemption or conversion rights. Our common stock is not subject to further calls or assessment by us. There are no redemption or sinking fund provisions applicable to the common stock. All shares of our common stock are fully paid and non-assessable. The rights, powers, preferences and privileges of holders of our common stock will be subject to those of the holders of any shares of our preferred stock we may authorize and issue in the future.

Preferred Stock

Our amended and restated certificate of incorporation authorizes our board of directors to establish one or more series of preferred stock (including convertible preferred stock). Unless required by law or by the NYSE, the authorized shares of preferred stock will be available for issuance without further action by you. Our board of directors may determine, with respect to any series of preferred stock, the powers, including preferences and relative participations, optional or other special rights, and the qualifications, limitations or restrictions, of that series, including, without limitation:

 

    the designation of the series;

 

    the number of shares of the series, which our board of directors may, except where otherwise provided in the preferred stock designation, increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares then outstanding);

 

    whether dividends, if any, will be cumulative or non-cumulative and the dividend rate of the series;

 

    the dates at which dividends, if any, will be payable;

 

    the redemption rights and price or prices, if any, for shares of the series;

 

    the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;

 

    the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding-up of our affairs;

 

    whether the shares of the series will be convertible into shares of any other class or series, or any other security, of us or any other corporation, and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates, any rate adjustments, the date or dates as of which the shares will be convertible and all other terms and conditions upon which the conversion may be made;

 

6


Table of Contents
    restrictions on the issuance of shares of the same series or of any other class or series; and

 

    the voting rights, if any, of the holders of the series.

We could issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition attempt or other transaction that some, or a majority, of the holders of our common stock might believe to be in their best interests or in which the holders of our common stock might receive a premium for their common stock over the market price of the common stock. Additionally, the issuance of preferred stock may adversely affect the rights of holders of our common stock by restricting dividends on the common stock, diluting the voting power of the common stock or subordinating the liquidation rights of the common stock. As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock.

Dividends

The DGCL permits a corporation to declare and pay dividends out of “surplus” or, if there is no “surplus,” out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. “Surplus” is defined as the excess of the net assets of the corporation over the amount determined to be the capital of the corporation by the board of directors. The capital of the corporation is typically calculated to be (and cannot be less than) the aggregate par value of all issued shares of capital stock. Net assets equals the fair value of total assets minus total liabilities. The DGCL also provides that dividends may not be paid out of net profits if, after the payment of the dividend, capital is less than the capital represented by the outstanding stock of all classes having a preference upon the distribution of assets.

Declaration and payment of any dividend will be subject to the discretion of our board of directors. The time and amount of dividends will be dependent upon our financial condition, operations, cash requirements and availability, debt repayment obligations, capital expenditure needs and restrictions in our debt instruments, industry trends, the provisions of Delaware law affecting the payment of distributions to stockholders and any other factors our board of directors may consider relevant.

We have no current plans to pay dividends on our common stock. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors that our board of directors may deem relevant. Because we are a holding company and have no direct operations, we will only be able to pay dividends from funds we receive from our subsidiaries. In addition, our ability to pay dividends will be limited by covenants in our existing indebtedness and may be limited by the agreements governing other indebtedness we or our subsidiaries incur in the future.

Annual Stockholder Meetings

Our amended and restated bylaws provide that annual stockholder meetings will be held at a date, time and place, if any, as exclusively selected by our board of directors. To the extent permitted under applicable law, we may conduct meetings by remote communications, including by webcast.

Anti-Takeover Effects of Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and Certain Provisions of Delaware Law

Our amended and restated certificate of incorporation, amended and restated bylaws and the DGCL contain provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile change of control and enhance the ability of our board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us.

 

7


Table of Contents

However, these provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition of the Company by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders.

Authorized but Unissued Capital Stock

Delaware law does not require stockholder approval for any issuance of authorized shares. However, the listing requirements of the NYSE, which would apply if and so long as our common stock remains listed on the NYSE, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common stock. Additional shares that may be used in the future may be issued for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions.

Our board of directors may generally issue preferred shares on terms calculated to discourage, delay or prevent a change of control of the Company or the removal of our management. Moreover, our authorized but unissued shares of preferred stock will be available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, to facilitate acquisitions and employee benefit plans.

One of the effects of the existence of unissued and unreserved common stock or preferred stock may be to enable our board of directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive our stockholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices.

Classified Board of Directors

Our amended and restated certificate of incorporation provides that our board of directors will be divided into three classes of directors, with the classes to be as nearly equal in number as possible, and with the directors serving three-year terms. As a result, approximately one-third of our board of directors will be elected each year. The classification of directors will have the effect of making it more difficult for stockholders to change the composition of our board of directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that, subject to any rights of holders of preferred stock to elect additional directors under specified circumstances, the number of directors will be fixed from time to time exclusively pursuant to a resolution adopted by the board of directors.

Business Combinations

We have opted out of Section 203 of the DGCL; however, our amended and restated certificate of incorporation contains similar provisions providing that we may not engage in certain “business combinations” with any “interested stockholder” for a three-year period following the time that the stockholder became an interested stockholder, unless:

 

    prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

 

    upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or

 

    at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 66-2/3% of our outstanding voting stock that is not owned by the interested stockholder.

 

8


Table of Contents

Generally, a “business combination” includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder” is a person who, together with that person’s affiliates and associates, owns, or within the previous three years owned, 15% or more of our outstanding voting stock. For purposes of this section only, “voting stock” has the meaning given to it in Section 203 of the DGCL.

Under certain circumstances, this provision will make it more difficult for a person who would be an “interested stockholder” to effect various business combinations with us for a three-year period. This provision may encourage companies interested in acquiring us to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if our board of directors approves either the business combination or the transaction which results in the stockholder becoming an interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.

Our amended and restated certificate of incorporation provides that Blackstone and its affiliates, and any of their respective direct or indirect transferees and any group as to which such persons are a party, do not constitute “interested stockholders” for purposes of this provision.

Removal of Directors; Vacancies

Under the DGCL, unless otherwise provided in our amended and restated certificate of incorporation, directors serving on a classified board may be removed by the stockholders only for cause. Our amended and restated certificate of incorporation provides that directors may be removed with or without cause upon the affirmative vote of a majority in voting power of all outstanding shares of stock entitled to vote generally in the election of directors, voting together as a single class; provided, however, at any time when Blackstone and its affiliates beneficially own in the aggregate, less than 40% of the voting power of all outstanding shares of our stock entitled to vote generally in the election of directors, directors may only be removed for cause, and only upon the affirmative vote of holders of at least 66-2/3% of the voting power of all the then outstanding shares of stock entitled to vote generally in the election of directors, voting together as a single class. In addition, our amended and restated certificate of incorporation also provides that, subject to the rights granted to one or more series of preferred stock then outstanding or the rights granted under the stockholders agreement with Blackstone, any vacancies on our board of directors will be filled only by the affirmative vote of a majority of the remaining directors, even if less than a quorum, by a sole remaining director or by the stockholders; provided, however, at any time when Blackstone and its affiliates beneficially own, in the aggregate, less than 40% in voting power of the stock of the Company entitled to vote generally in the election of directors, any newly created directorship on the board of directors that results from an increase in the number of directors and any vacancy occurring in the board of directors may only be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director (and not by the stockholders). Since March 9, 2015, Blackstone and its affiliates have beneficially owned, in the aggregate, less than 40% of the voting power of the stock of the Company.

No Cumulative Voting

Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. Our amended and restated certificate of incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our stock entitled to vote generally in the election of directors will be able to elect all our directors.

Special Stockholder Meetings

Our amended and restated certificate of incorporation provides that special meetings of our stockholders may be called at any time only by or at the direction of the board of directors or the chairman of the board of

 

9


Table of Contents

directors; provided, however, at any time when Blackstone and its affiliates beneficially own, in the aggregate, at least 40% in voting power of the stock entitled to vote generally in the election of directors, special meetings of our stockholders shall also be called by the board of directors or the chairman of the board of directors at the request of Blackstone and its affiliates. Our amended and restated bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control or management of the Company. Since March 9, 2015, Blackstone and its affiliates have beneficially owned, in the aggregate, less than 40% of the voting power of the stock of the Company.

Director Nominations and Stockholder Proposals

Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be “properly brought” before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder’s notice must be received at our principal executive offices neither less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. Our amended and restated bylaws also specify requirements as to the form and content of a stockholder’s notice. These provisions will not apply to Blackstone and its affiliates so long as the stockholders agreement remains in effect. Our amended and restated bylaws allow the chairman of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to influence or obtain control of the Company.

Stockholder Action by Written Consent

Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless our amended and restated certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation precludes stockholder action by written consent at any time when Blackstone and its affiliates own, in the aggregate, less than 40% in voting power of our stock entitled to vote generally in the election of directors. Since March 9, 2015, Blackstone and its affiliates have beneficially owned, in the aggregate, less than 40% of the voting power of the stock of the Company.

Supermajority Provisions

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the board of directors is expressly authorized to make, alter, amend, change, add to, rescind or repeal, in whole or in part, our bylaws without a stockholder vote in any matter not inconsistent with the laws of the State of Delaware or our amended and restated certificate of incorporation. For as long as Blackstone and its affiliates beneficially own, in the aggregate, at least 40% in voting power of our stock entitled to vote generally in the election of directors, any amendment, alteration, change, addition or repeal of our bylaws by our stockholders requires the affirmative vote of a majority in voting power of the outstanding shares of our stock present in person or represented by proxy and entitled to vote on such amendment, alteration, rescission or repeal. At any time when Blackstone and its affiliates beneficially own, in the aggregate, less than 40% in voting power of our stock entitled to vote generally in the election of directors, any amendment, alteration, rescission or repeal of our bylaws by our stockholders requires the affirmative vote of the holders of at least 66-2/3% in voting power of all the then outstanding shares of stock entitled to vote thereon, voting together as a single class.

 

10


Table of Contents

The DGCL provides generally that the affirmative vote of a majority of the outstanding shares entitled to vote thereon, voting together as a single class, is required to amend a corporation’s certificate of incorporation, unless the certificate of incorporation requires a greater percentage.

Our amended and restated certificate of incorporation provides that at any time when Blackstone and its affiliates beneficially own, in the aggregate, less than 40% in voting power of our stock entitled to vote generally in the election of directors, the following provisions in our amended and restated certificate of incorporation may be amended, altered, repealed or rescinded only by the affirmative vote of the holders of at least 66-2/3% in voting power of the then outstanding shares of our stock entitled to vote thereon, voting together as a single class:

 

    the provision requiring a 66-2/3% supermajority vote for stockholders to amend our bylaws;

 

    the provisions providing for a classified board of directors (the election and term of our directors);

 

    the provisions regarding resignation and removal of directors;

 

    the provisions regarding competition and corporate opportunities;

 

    the provisions regarding entering into business combinations with interested stockholders;

 

    the provisions regarding stockholder action by written consent;

 

    the provisions regarding calling special meetings of stockholders;

 

    the provisions regarding filling vacancies on our board of directors and newly created directorships;

 

    the provisions eliminating monetary damages for breaches of fiduciary duty by a director; and

 

    the amendment provision requiring that the above provisions be amended only with a 66-2/3% supermajority vote.

The combination of the classification of our board of directors, the lack of cumulative voting and the supermajority voting requirements will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management.

These provisions may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management or the Company, such as a merger, reorganization or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of the Company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions are also intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management.

Since March 9, 2015, Blackstone and its affiliates have beneficially owned, in the aggregate, less than 40% of the voting power of the stock of the Company.

Dissenters’ Rights of Appraisal and Payment

Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of us. Pursuant to the DGCL, stockholders who properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery.

 

11


Table of Contents

Stockholders’ Derivative Actions

Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action; provided that the stockholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such stockholder’s stock thereafter devolved by operation of law.

Exclusive Forum

Our amended and restated certificate of incorporation provides that unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (i) derivative action or proceeding brought on behalf of our Company, (ii) action asserting a claim of breach of a fiduciary duty owed by any director or officer of our Company to the Company or the Company’s stockholders, creditors or other constituents, (iii) action asserting a claim against the Company or any director or officer of the Company arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or our amended and restated bylaws or (iv) action asserting a claim against the Company or any director or officer of the Company governed by the internal affairs doctrine, in each such case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants in such action. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of our Company shall be deemed to have notice of and consented to the forum provisions in our amended and restated certificate of incorporation.

Conflicts of Interest

Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. Our amended and restated certificate of incorporation, to the maximum extent permitted from time to time by Delaware law, renounces any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to our officers, directors or stockholders or their respective affiliates, other than those officers, directors, stockholders or affiliates who are our or our subsidiaries’ employees. Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, none of Blackstone or any of its affiliates or any director who is not employed by us (including any non-employee director who serves as one of our officers in both his director and officer capacities) or his or her affiliates will have any duty to refrain from (i) engaging in a corporate opportunity in the same or similar lines of business in which we or our affiliates now engage or propose to engage or (ii) otherwise competing with us or our affiliates. In addition, to the fullest extent permitted by law, in the event that Blackstone or any non-employee director acquires knowledge of a potential transaction or other business opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for us or our affiliates, such person will have no duty to communicate or offer such transaction or business opportunity to us or any of our affiliates and they may take any such opportunity for themselves or offer it to another person or entity. Our amended and restated certificate of incorporation does not renounce our interest in any business opportunity that is expressly offered to a non-employee director solely in his or her capacity as a director or officer of the Company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us unless we would be permitted to undertake the opportunity under our amended and restated certificate of incorporation, we have sufficient financial resources to undertake the opportunity and the opportunity would be in line with our business.

Limitations on Liability and Indemnification of Officers and Directors

The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties, subject to certain exceptions. Our amended and restated certificate of incorporation includes a provision that eliminates the

 

12


Table of Contents

personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL. The effect of these provisions is to eliminate the rights of us and our stockholders, through stockholders’ derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation does not apply to any director if the director has acted in bad faith, knowingly or intentionally violated the law, authorized illegal dividends or redemptions or derived an improper benefit from his or her actions as a director.

Our amended and restated bylaws provide that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the DGCL. We also are expressly authorized to carry directors’ and officers’ liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers.

The limitation of liability, advancement and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

We currently are party to indemnification agreements with certain of our directors and officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. These agreements will require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

Listing

Our common stock is listed on the New York Stock Exchange under the symbol “CTLT”.

 

13


Table of Contents

PLAN OF DISTRIBUTION

We and/or the selling stockholders, if applicable, may sell the shares of our common stock covered by this prospectus in any of the following ways (or in any combination):

 

    to or through underwriters or dealers;

 

    directly to one or more purchasers;

 

    through agents; or

 

    through a combination of any of these methods of sale.

Each time that we sell shares of our common stock covered by this prospectus, we will provide a prospectus supplement that will describe the method of distribution and set forth the terms and conditions of the offering of such shares, including:

 

    the name or names of any underwriters, dealers or agents and the amounts of shares underwritten or purchased by each of them;

 

    the offering price of the shares and the proceeds to us and/or the selling stockholders, if applicable, and any underwriting discounts, commissions, concessions or agency fees allowed or reallowed or paid to dealers;

 

    any options under which underwriters may purchase additional shares from us and/or the selling stockholders; and

 

    any securities exchange or market on which the shares may be listed or traded.

Any offering price and any discounts, commissions, concessions or agency fees allowed or reallowed or paid to dealers may be changed from time to time. We may determine the price or other terms of the shares of our common stock offered under this prospectus by use of an electronic auction. We will describe how any auction will determine the price or any other terms, how potential investors may participate in the auction and the nature of the obligations of the underwriter, dealer or agent in the applicable prospectus supplement.

We and/or the selling stockholders, if applicable, may distribute the shares from time to time in one or more transactions:

 

    at a fixed price or at prices that may be changed from time to time;

 

    at market prices prevailing at the time of sale;

 

    at prices relating to such prevailing market prices; or

 

    at negotiated prices.

Underwriters, dealers or any other third parties described above may offer and sell the offered shares from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. If underwriters or dealers are used in the sale of any shares, the shares will be acquired by the underwriters or dealers for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The shares may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters. Generally, the underwriters’ obligations to purchase the shares will be subject to certain conditions precedent. The underwriters will be obligated to purchase all of the shares if they purchase any of the shares (other than any shares purchased upon exercise of any over-allotment option), unless otherwise specified in the prospectus supplement. We may use underwriters with whom we have a material relationship. We will describe the nature of any such relationship in the prospectus supplement, naming the underwriter or underwriters.

 

14


Table of Contents

We and/or the selling stockholders, if applicable, may sell the shares through agents from time to time. The prospectus supplement will name any agent involved in the offer or sale of the shares and any commissions paid to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment. We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the shares from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. These contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions to be paid for solicitation of these contracts. Any underwriters, broker-dealers and agents that participate in the distribution of the shares may be deemed to be “underwriters” as defined in the Securities Act. Any commissions paid or any discounts or concessions allowed to any such persons, and any profits they receive on resale of the shares, may be deemed to be underwriting discounts and commissions under the Securities Act. We will identify any underwriters or agents and describe their compensation in a prospectus supplement.

Offered shares may also be offered and sold, if so indicated in the applicable prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more marketing firms, acting as principals for their own accounts or as agents for us. Any remarketing firm will be identified and the terms of its agreements, if any, with us and its compensation will be described in the applicable prospectus supplement.

Underwriters or agents may purchase and sell the shares in the open market. These transactions may include over-allotment, stabilizing transactions, syndicate covering transactions and penalty bids.

Over-allotment involves sales in excess of the offering size, which creates a short position. Stabilizing transactions consist of bids or purchases for the purpose of preventing or retarding a decline in the market price of the shares and are permitted so long as the stabilizing bids do not exceed a specified maximum. Syndicate covering transactions involve the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase to reduce a short position created in connection with the offering. The underwriters or agents also may impose a penalty bid, which permits them to reclaim selling concessions allowed to syndicate members or certain dealers if they repurchase the shares in stabilizing or covering transactions. These activities may stabilize, maintain or otherwise affect the market price of the shares, which may be higher than the price that might otherwise prevail in the open market. These activities, if begun, may be discontinued at any time. These transactions may be effected on any exchange on which the shares are traded, in the over-the-counter market or otherwise.

Our common stock is listed on the New York Stock Exchange under the symbol “CTLT”.

If at the time of any offering made under this prospectus a member of FINRA participating in the offering has a “conflict of interest” as defined in FINRA’s Rule 5121 (“Rule 5121”), that offering will be conducted in accordance with the relevant provisions of Rule 5121.

There can be no assurance that we will sell all or any of the shares of common stock offered by this prospectus.

Agents, dealers and underwriters may be entitled to indemnification by us and the selling stockholders against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments which the agents, dealers or underwriters may be required to make in respect thereof.

The specific terms of the lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.

 

15


Table of Contents

LEGAL MATTERS

Unless we state otherwise in the applicable prospectus supplement, the validity of the shares of common stock will be passed upon for us by Simpson Thacher & Bartlett LLP, New York, New York. An investment vehicle comprised of selected partners of Simpson Thacher & Bartlett LLP, members of their families, related persons and others owns an interest representing less than 1% of the capital commitments of funds affiliated with The Blackstone Group L.P.

EXPERTS

Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements and schedule included in our 2015 Form 10-K, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements and schedule are incorporated by reference in reliance on Ernst & Young LLP’s report given on their authority as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

This prospectus is a part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference in this prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at http://www.sec.gov. You may also read and copy any document we file at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room.

INFORMATION INCORPORATED BY REFERENCE

The rules of the SEC allow us to incorporate information into this prospectus by reference. The information incorporated by reference is considered to be a part of this prospectus. This prospectus incorporates by reference the documents listed below and all documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus, from their respective filing dates:

 

    our Annual Report on Form 10-K for the fiscal year ended June 30, 2015 and Amendment No. 1 to such annual report on Form 10-K/A filed on November 3, 2015;

 

    our Quarterly Reports on Form 10-Q for the periods ended September 30, 2015, December 31, 2015 and March 31, 2016;

 

    our Definitive Proxy Statement on Schedule 14A, filed on September 16, 2015 (solely those portions that were incorporated by reference into Part III of our Annual Report on Form 10-K for the fiscal year ended June 30, 2015);

 

    our Current Reports on Form 8-K, filed on July 30, 2015, October 30, 2015, November 3, 2015 (excluding information under Item 2.02 and Item 9.01), November 16, 2015 and April 29, 2016; and

 

    the description of our common stock contained in our Registration Statement on Form 8-A filed on July 31, 2014, including all amendments and reports filed for the purpose of updating such description.

 

16


Table of Contents

Any statement made in this prospectus or in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

You can obtain any of the filings incorporated by reference into this prospectus through us or from the SEC through the SEC’s website at http://www.sec.gov. We will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral request of such person, a copy of any or all of the reports and documents referred to above which have been or may be incorporated by reference into this prospectus. You should direct requests for those documents to:

Catalent, Inc.

14 Schoolhouse Road

Somerset, NJ 08873

Attn: Corporate Secretary

Tel.: (732) 537-6200

Email: CorpSec@catalent.com

Our reports and documents incorporated by reference into this prospectus may also be found in the “Investors” section of our website at www.catalent.com. Our website and the information contained in it or connected to it shall not be deemed to be incorporated into this prospectus or any registration statement of which it forms a part.

 

17


Table of Contents

 

 

Catalent, Inc.

Common Stock

 

LOGO

 

 

PROSPECTUS

 

 

June 6, 2016

 

 

 

 

 


Table of Contents

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

 

ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.

The following table sets forth the expenses payable by the Registrant expected to be incurred in connection with the issuance and distribution of the shares of common stock being registered hereby (other than underwriting discounts and commissions). All of such expenses are estimates, other than the filing fees payable to the Securities and Exchange Commission and the Financial Industry Regulatory Authority, Inc.

 

Filing Fee—Securities and Exchange Commission

   $ *   

Fee—Financial Industry Regulatory Authority, Inc.

     225,500   

Fees and Expenses of Counsel

     **   

Printing Expenses

     **   

Fees and Expenses of Accountants

     **   

Miscellaneous Expenses

     **   
  

 

 

 

Total

   $ **   
  

 

 

 

 

* Omitted because the registration fee is being deferred pursuant to Rule 456(b).
** Estimated expenses are not presently known. To the extent required, any applicable prospectus supplement will set forth the estimated aggregate amount of expenses payable in respect of any offering of securities.

 

ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

Section 102(b)(7) of the Delaware General Corporation Law, or DGCL, allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation provides for this limitation of liability.

Section 145 of the DGCL, or Section 145, provides, among other things, that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who were or are a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation’s best interests, provided further that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him against the expenses which such officer or director has actually and reasonably incurred.

 

II-1


Table of Contents

Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify him or her under Section 145.

Our amended and restated bylaws provides that we must indemnify our directors and officers to the fullest extent authorized by the DGCL and must also pay expenses incurred in defending any such proceeding in advance of its final disposition upon delivery of an undertaking, by or on behalf of an indemnified person, to repay all amounts so advanced if it should be determined ultimately that such person is not entitled to be indemnified under this section or otherwise.

The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our amended and restated certificate of incorporation, our amended and restated bylaws, agreement, vote of stockholders or disinterested directors or otherwise.

We maintain standard policies of insurance that provide coverage (1) to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (2) to us with respect to indemnification payments that we may make to such directors and officers.

 

ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

See the attached Exhibit Index, which is incorporated herein by reference.

 

ITEM 17. UNDERTAKINGS

 

(1) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

 

(2) The undersigned Registrant hereby undertakes:

 

  (A) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

  (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

 

  (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

II-2


Table of Contents
  (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, that paragraphs (2)(A)(i), (2)(A)(ii) and (2)(A)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

 

  (B) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  (C) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

  (D) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

 

  (i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

 

  (ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

 

  (E) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

  (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

  (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

II-3


Table of Contents
  (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

  (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

(3) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-4


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Somerset, State of New Jersey, on the 6th day of June, 2016.

 

CATALENT, INC.
By:    /s/ John Chiminski
  Name: John Chiminski
  Title:   President and Chief Executive Officer

POWER OF ATTORNEY

Know all men by these presents, that each person whose signature appears below hereby constitutes and appoints Matthew Walsh, John Chiminski and Steven Fasman, and each of them, any of whom may act without joinder of the other, the individual’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any or all amendments, including post-effective amendments to the Registration Statement, including a prospectus or an amended prospectus therein and any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact as agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement and Power of Attorney have been signed by the following persons in the capacities indicated on the 6th day of June, 2016.

 

Signature

  

Title

/s/ John Chiminski

  

Chief Executive Officer and Director

(Principal Executive Officer)

John Chiminski   

/s/ Chinh E. Chu

  

Chairman of the Board of Directors

Chinh E. Chu   

/s/ Melvin D. Booth

   Director
Melvin D. Booth   

/s/ J. Martin Carroll

   Director
J. Martin Carroll   

/s/ Rolf Classon

   Director
Rolf Classon   

 

II-5


Table of Contents

/s/ Gregory T. Lucier

   Director
Gregory T. Lucier   

/s/ Bruce McEvoy

   Director
Bruce McEvoy   

/s/ Donald E. Morel Jr.

   Director
Donald E. Morel Jr.   

/s/ James Quella

   Director
James Quella   

/s/ Jack Stahl

   Director
Jack Stahl   

/s/ Matthew Walsh

  

Executive Vice President and Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

Matthew Walsh   

 

II-6


Table of Contents

(a) Exhibit Index

 

  1.1*    Form of Underwriting Agreement
  3.1    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 5, 2014, File No. 001-36587)
  3.2    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 5, 2014, File No. 001-36587)
  5.1    Opinion of Simpson Thacher & Bartlett LLP regarding validity of the shares of common stock registered
10.1    Stockholders Agreement, dated as of August 5, 2014, between Catalent, Inc. and Blackstone Healthcare Partners L.L.C. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 5, 2014, File No. 001-36587)
10.2    Registration Rights Agreement, dated as of August 5, 2014, by and among Catalent, Inc. and certain of its stockholders (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on August 5, 2014, File No. 001-36587)
23.1    Consent of Ernst & Young LLP
23.2    Consent of Simpson Thacher & Bartlett LLP (included as part of Exhibit 5.1)
24.1    Power of Attorney (included on signature pages to this Registration Statement)

 

* To be filed, if necessary, by amendment or as an exhibit to a Current Report on Form 8-K and incorporated by reference herein.

 

II-7

EX-5.1 2 d192455dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

SIMPSON THACHER & BARTLETT LLP

425 LEXINGTON AVENUE

NEW YORK, N.Y. 10017-3954

(212) 455-2000

FACSIMILE (212) 455-2502

June 6, 2016

Catalent, Inc.

14 Schoolhouse Road

Somerset, New Jersey 08873

Ladies and Gentlemen:

We have acted as counsel to Catalent, Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3 (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to shares of common stock of the Company, par value $0.01 per share (the “Common Stock”). The Common Stock may be issued and sold or delivered from time to time as set forth in the Registration Statement, any amendment thereto, the prospectus contained therein (the “Prospectus”) and supplements to the Prospectus and pursuant to Rule 415 under the Securities Act.

We have examined the Registration Statement, the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws of the Company. We also have examined the originals, or duplicates or certified or conformed copies, of such records, agreements, documents and other instruments and have made such other investigations as we have deemed relevant and necessary in connection with the opinion hereinafter set forth. As to questions of fact material to this opinion, we have relied upon certificates or comparable documents of public officials and of officers and representatives of the Company.


In rendering the opinion set forth below, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or certified or conformed copies and the authenticity of the originals of such latter documents.

Based upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that, assuming (a) the taking of all necessary corporate action to authorize and approve the issuance of the Common Stock and (b) the due issuance and delivery of the Common Stock, upon payment therefor in accordance with the applicable definitive underwriting agreement approved by the Board of Directors of the Company, the Common Stock will be validly issued, fully paid and nonassessable.

We do not express any opinion herein concerning any law other than the Delaware General Corporation Law.

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the use of our name under the caption “Legal Matters” in the Prospectus included in the Registration Statement.

Very truly yours,

/s/ Simpson Thacher & Bartlett LLP

SIMPSON THACHER & BARTLETT LLP

EX-23.1 3 d192455dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-3) and related Prospectus of Catalent, Inc. for the registration of shares of its common stock and to the incorporation by reference therein of our report dated September 2, 2015, with respect to the consolidated financial statements and schedule of Catalent, Inc. and subsidiaries included in its Annual Report (Form 10-K) for the year ended June 30, 2015, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

MetroPark, New Jersey

June 6, 2016

GRAPHIC 4 g192455g41h44.jpg GRAPHIC begin 644 g192455g41h44.jpg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